NCT00237809View on ClinicalTrials.gov

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

December 31, 2010

Study Completion Date

September 30, 2012

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

D-serine

D-serine (30 mg/kg)

BEHAVIORAL

Cognitive Retraining (CRT)

Cognitive retraining therapy (CRT)

DRUG

Placebo

Placebo D-serine Drug

BEHAVIORAL

Cognitive Retraining Placebo

Cognitive retraining therapy (CRT) control

Trial Locations (2)

06508

Connecticut Mental Health Center, New Haven

06516

VA Connecticut Healthcare System, West Haven

Sponsors
All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

Donaghue Medical Research Foundation

OTHER

lead

Yale University

OTHER